# 23andMe account plan

> 23andMe is a consumer DNA testing and genetic research business, run as a nonprofit with more than 11 million research participants.

## At a glance

23andMe sells personalized DNA testing and runs genetic research services for consumers and scientists. Since July 2025 it is owned by TTAM Research Institute, a California nonprofit founded and led by co-founder Anne Wojcicki, which bought the business lines out of the Chapter 11 case of 23andMe Holding Co. for $305 million. The nonprofit now operates as 23andMe Research Institute, a 501(c)(3) research organization based in Palo Alto. It says it has more than 11 million consented research participants; no revenue or profit figures are published in the documents read.

## Business units

- **Personal Genome Service**: The consumer DNA testing business, including ancestry and health-risk reports. Products named in the documents include Total Health, which combines exome sequencing with blood testing. It continues to operate after the July 2025 acquisition.
- **Research Services**: The research business that works with the consented participant community. The Institute is the recruitment partner for the Scripps Wellderly Brain Study and says it works with qualified researchers and connects genetics with de-identified real-world health data.
- **Lemonaid Health**: A telemedicine service that 23andMe purchased for about $400 million in 2021 and that ABC News reported was included in the acquisition. The documents do not describe its current operations.

## Strategic priorities

- **Grow the research cohort**: Anne Wojcicki says the company is at 14 million people and points to a hundred million as the next milestone, because AI models for DNA need far larger datasets.
- **Disease prediction and prevention**: Wojcicki says 23andMe is very focused on one area, disease prediction, so people at risk can be found and disease caught at the earliest stages.
- **Open genetic data to qualified researchers**: The Institute says it is working with qualified researchers and is committed to expanding access to genetic and phenotypic data, including links to de-identified real-world health data.
- **Recruit participants for external studies**: The Institute is the recruitment partner for the Wellderly Brain Study, which plans to screen and randomize roughly 1,200 at-risk participants over an estimated 14-16 months.
- **Stay a neutral, trusted data owner**: Wojcicki says the owner of genetic information should not be owned by a single pharma company. TTAM committed to customer choice and transparency, including the option to change a decision on research participation.

## Latest results

The documents give no financial results. The latest operating news is from autumn 2026: on 2026-10-13 the Institute formed a Scientific Advisory Board, on 2026-10-19 it announced its ASHG 2026 presentations, citing more than 11 million consented research participants, and on 2026-11-11 it announced the Scripps Alzheimer's prevention partnership.

## Investments and deals

- **Acquisition out of bankruptcy**: TTAM Research Institute completed the acquisition of the Personal Genome Service and Research Services business lines on 2025-07-14 for $305 million, after a court approval reported by ABC News on 2025-07-01. It replaced a $256 million bid by Regeneron Pharmaceuticals.
- **Scientific Advisory Board**: Formed in October 2026 with six named members across genomics, AI, gene editing, infectious disease and clinical medicine, alongside the Board of Directors and a Privacy Advisory Board.
- **Linked health data**: Wojcicki says about half a million customers link wearable data, and 50 plus thousand people consent to share medical records, to combine with genetics and AI.

## Challenges and risks

- **Privacy and consent scrutiny**: 27 states and the District of Columbia sued to block a sale of genetic information without customer consent before the sale was approved. TTAM said it plans to maintain the privacy policies and add further data security measures.
- **Aftermath of the bankruptcy**: 23andMe filed for Chapter 11 in March 2025 after a 2023 class-action settlement over a data breach and a mass board resignation in 2024. Wojcicki says she was surprised how many people backed away from helping during the bankruptcy.
- **Scale of data needed**: Wojcicki says 14 million is not enough for the next stage and that models need to be trained on DNA at much larger scale.
- **Study recruitment is hard**: The Scripps release says recruitment can be a significant obstacle in clinical research, which the Institute is positioned to address through its recontactable participant community.

## What leadership says

> "we're at 14 million today. I point to a hundred million as sort of the next milestone." — Anne Wojcicki, Founder and CEO of 23andMe Research Institute, Silicon Valley Girl Podcast, 2026-07-28

> "This is an extraordinary group of scientific leaders who will help advance our mission to unravel the mysteries of the human genome and make those discoveries accessible to everyone" — Anne Wojcicki, Founder and CEO of 23andMe Research Institute, Scientific Advisory Board press release, 2026-10-13

> "With more than 11 million consented participants, we can ask questions that simply weren't answerable before" — Adam Auton, Vice President of Research, ASHG 2026 press release, 2026-10-19

> "Our approach allows us to recruit for studies with a level of precision and scale that has traditionally been difficult to achieve" — Noura Abul-Husn, M.D., Ph.D., Chief Medical Officer, Scripps partnership press release, 2026-11-11


## Where a supplier can help

- **Research partnerships and recruitment**: Sponsors of clinical studies could use the Institute's recruitment service, tied to its role as recruitment partner for the Wellderly Brain Study and the goal of growing the cohort.
- **Data and AI infrastructure**: Suppliers of secure data platforms and AI tooling for genomic datasets fit the priority of training models on DNA at larger scale and the work on de-identified real-world health data.
- **Privacy, security and compliance**: Security and privacy vendors fit the challenge of consent scrutiny and TTAM's commitment to add data security measures and keep a Privacy Advisory Board.
- **Health data connections**: Connectors for wearable and medical-record data fit the investment in linking customer health data to genetics.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Stop Disease 5 Years Early: AI + DNA Playbook With 23andMe's Founder Anne Wojcicki (Silicon Valley Girl Podcast)](https://marinamogilko.co/episode/VF2FwZ_PXhw/)

Podcast · Anne Wojcicki, Co-founder and CEO of 23andMe Research Institute · 2026-07-28

- Wojcicki says 23andMe has "14 million" people and points to "a hundred million" as the next milestone, because AI models for DNA need far larger datasets.
- She cites a publication from her team showing that "at over a million people" training models with AI starts to give nonlinear improvements in risk prediction.
- The company is "very focused" on one area, disease prediction: finding who is at risk and catching disease at the earliest stages.
- After bankruptcy she bought the company back through a court-approved auction; she says the owner of genetic data "should be a neutral party" and "should not be owned by a single pharma company".
- 23andMe pulls in wearable data (about half a million customers linked via Apple HealthKit) and medical records from 50 plus thousand consenting people.
- She names three products, including Total Health (exome sequencing plus blood), and says she is an investor in a whole-body scan service she uses every year.
- She says she has 175 people at the company and a management team that frees her time.
- She wonders whether 23andMe should create a retail store; a 23andMe lung cancer study is running, tied to the Susan Wojcicki Foundation.

### [Court approves sale of 23andMe to nonprofit led by former CEO Anne Wojcicki (ABC News)](https://abcnews.com/Business/court-approves-sale-23andme-nonprofit-led-former-ceo/story?id=123369272)

Report · 2025-07-01

- A US bankruptcy court approved the $305 million sale of 23andMe to TTAM Research Institute, a California nonprofit led by co-founder and former CEO Anne Wojcicki.
- The assets include genetic data belonging to roughly 15 million customers and the telemedicine service Lemonaid Health, bought for about $400 million in 2021.
- TTAM's bid replaced a $256 million bid announced in May by Regeneron Pharmaceuticals.
- 27 states and the District of Columbia had sued to block a sale of genetic data without customer consent.
- TTAM said it will keep the customer privacy policies and add further data security measures.
- Wojcicki said TTAM aims to operate for "the public good".

### [TTAM Research Institute completes the acquisition of 23andMe assets (press release)](https://mediacenter.23andme.com/press-releases/ttam-research-institute-nonprofit-public-benefit-corporation/)

Report · 2025-07-14

- On 2025-07-14 TTAM Research Institute, a California nonprofit public benefit corporation founded and led by Anne Wojcicki, completed its acquisition of 23andMe's Personal Genome Service and Research Services business lines under Section 363 of the US Bankruptcy Code.
- The seller was 23andMe Holding Co. and its debtor subsidiaries, which had filed Chapter 11.
- As part of TTAM, 23andMe "is continuing to operate and provide customers with personalized DNA testing and research services".
- TTAM says customers keep the option to change their decision on whether to participate in research.
- TTAM describes itself as a nonprofit medical research organization that wants everyone to access their individual genetic code and contribute it to research.

### [23andMe Research Institute Announces Inaugural Scientific Advisory Board (press release)](https://www.23andme.org/media-center/press-releases/23andme-research-institute-announces-inaugural-scientific-advisory-board/)

Report · 2026-10-13

- On 2026-10-13 the nonprofit 23andMe Research Institute announced its first Scientific Advisory Board.
- The board covers genomics, artificial intelligence, gene editing, infectious disease and clinical medicine.
- Named members include Russ Altman, Alexis Battle, Robert Califf, David Liu, Pardis Sabeti and Eric Topol.
- The board will advise on research priorities, program design, grant applications, regulatory considerations and partnerships between genomics, artificial intelligence and healthcare.
- It joins the Institute's Board of Directors and Privacy Advisory Board.

### [23andMe Research Institute to Showcase Scientific Impact and Expanded Research Capabilities at ASHG 2026 (press release)](https://www.23andme.org/media-center/press-releases/23andme-research-institute-to-showcase-scientific-impact-and-expanded-research-capabilities-at-ashg-2026/)

Report · 2026-10-19

- 23andMe Research Institute, a nonprofit, will present at the ASHG 2026 meeting (Montréal, October 20-24) using "more than 11 million consented research participants".
- It will present four presentations and posters on clinical genetics, disease biology and new analytical methods.
- New capabilities connect genetics with de-identified real-world health data, giving scientists clinical context.
- It is working with qualified researchers to extend its research and says it is committed to expanding access to genetic and phenotypic data.
- Named executives: Adam Auton, Vice President of Research, and Noura Abul-Husn, Chief Medical Officer.
- Scientists can contact the business development address bd@23andme.org.

### [23andMe Research Institute and Scripps Research Translational Institute partner on Alzheimer's prevention research (press release)](https://www.23andme.org/media-center/press-releases/23andme-research-institute-and-scripps-research-announce-partnership/)

Report · 2026-11-11

- On 2026-11-11 23andMe Research Institute, a nonprofit 501(c)(3), announced a partnership with Scripps Research Translational Institute.
- The Institute is the recruitment partner for the Wellderly Brain Study on Alzheimer's prevention through digital lifestyle coaching.
- The study is estimated to run over 14-16 months and intends to screen and randomize roughly 1,200 at-risk participants.
- 23andMe sends notifications to eligible participants who opted to learn about research opportunities.
- Chief Medical Officer Noura Abul-Husn says direct engagement of consented participants lets it design studies that are "more targeted, more efficient, and ultimately more informative".
- The release calls 23andMe the holder of "the world's largest recontactable community of consented research participants".

## Questions about 23andMe

### What does 23andMe do?

23andMe offers personalized DNA testing for consumers and research services built on a consented participant community. It operates as the nonprofit 23andMe Research Institute.

### Who owns 23andMe?

TTAM Research Institute, a California nonprofit founded and led by Anne Wojcicki, completed the acquisition of the Personal Genome Service and Research Services business lines on 2025-07-14. The price was $305 million.

### How many research participants does 23andMe have?

The Institute's October 2026 release cites more than 11 million consented research participants. In July 2026 Wojcicki spoke of 14 million people and a goal of a hundred million.

### Who leads 23andMe?

Anne Wojcicki, the co-founder, is Founder and CEO of 23andMe Research Institute. Adam Auton is Vice President of Research and Noura Abul-Husn is Chief Medical Officer.

### What is the 23andMe strategy?

The stated focus is disease prediction and prevention, a much larger research cohort, partnerships with researchers, and combining genetics with health data and AI.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)_
